Opinions
Keith Richards
Prometic Life Sciences Inc.
PLI-T
HOLD
Dec 30, 2016
Stock price when the opinion was issued
You might be interested:
He believes this has been very volatile due to an overhang and the potential need for more financing. It is stabilizing now and they have received an investment from the Thompson family. He thinks they should begin to receive approval soon with sales later this year. They do not own it presently, although they have held it in the past.
He is short this company presently. The market cap is quite high compared to his estimate of value. The company appears to be quite promotional compared to others. Their plasma protein product is easy to get through the FDA and subject to hype at each easy approval stage. He does not see revenues and earnings to back it up.
They have patents on plasma protein drugs that are interesting. The company had significant success pushing these through the FDA stages but they recently ran into a delay and the stock dropped precipitously. He has been short for a while thinking the market cap was overvalued for the ultimate end market they were pursuing. Now that the stock has dropped so much, his short position is smaller. This is a highly speculative position.
This has a choppy looking chart, but there is a little bit of progress. It looked like it had broken down through its somewhat upward slanting trend line. It doesn’t look like a clean stock to buy, but there is definitely some rhythm to it. It appears that whenever it approaches the longer-term trend line, it is a good place to Buy. This could very well get back to that zone of $3-$3.50. It might not be a bad trade.